Background: There is increasing focus on transcatheter heart valve (THV) thrombosis.
Introduction
Transcatheter aortic valve replacement (TAVR) is a well-established treatment of severe aortic stenosis. Owing to technical improvements, increased operator experience and refined preprocedural imaging, it is an increasingly safe and successful procedure (1, 2) . However, there is increasing awareness of prosthesis valve thrombosis after TAVR (3) (4) (5) (6) . Accordingly, recent reports have demonstrated that conventional post-TAVR transthoracic echocardiography (TTE) follow-up is inferior for the detection of transcatheter heart valve (THV) thrombosis when compared to contrast-enhanced multidetector computed tomography (MDCT). Indeed, post-TAVR MDCT has the ability to detect THV thrombosis in asymptomatic patients with no evidence of THV obstruction on TTE (3) (4) (5) . Although often subclinical, THV thrombosis may potentially lead to increased risk of stroke, THV obstruction with heart failure or reduced longterm THV durability, making early detection pivotal to guide treatment. Current evidence regarding THV thrombosis mainly builds on case series and small studies of non-consecutive patients with short follow-up time (3) (4) (5) (6) . Consequently, the incidence, clinical implications and predisposing factors of THV thrombosis remain to be fully understood. The aim of this study was to assess the incidence, potential predictors, and clinical implications of THV thrombosis after TAVR with a balloon-expandable THV.
Methods

Study population and transcatheter aortic valve replacement procedure
Among 460 consecutive patients undergoing TAVR with the Edwards Sapien XT or TAVR was performed according to standard practice (7) . THV size selection was based on MDCT analysis, and balloon under-/overfilling and post-dilatation was performed in selected cases (8, 9) .
Standard post-TAVR antithrombotic treatment comprised dual antiplatelet therapy with aspirin (75 mg/day) and clopidogrel (75 mg/day) for 12 months followed by lifelong aspirin (75 mg/day) (3) .In patients with atrial fibrillation, the decision on treatment with warfarin alone or in combination with one platelet inhibitor was at the discretion of the treating physician.
Echocardiographic assessment
TTE was performed before discharge and at routine follow-up visit 1 and 2. THV function was assessed by the mean trans-THV gradient and the effective orifice area (EOA THV ).
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Multidetector computed tomography analysis
MDCT examinations were analyzed using commercially available software (syngo.via and Multimodality Workplace, Siemens Healthcare, Forcheim, Germany). On pre-TAVR MDCT scans, aortic root dimensions and degree of calcification was determined as previously described (7) . Post-TAVR MDCT scans were evaluated for hypo-attenuated leaflet thickening indicating THV thrombosis (3) . Leaflet thrombus was defined as hypo-attentuating leaflet thickening or a more focal hypo-attenuating abnormality attached to the THV leaflet and/or diffuse thickening of 1 or more THV leaflets. The finding had to be identifiable on at least two reconstructed planes (double-oblique axial and multiplanar reformatted reconstructions). In the event of THV thrombosis, the number of leaflets involved as well as maximal leaflet thickening was assessed.
THV dimensions, eccentricity, and expansion were assessed as previously described (3) . THV underexpansion was defined as an expansion ratio of ≤90% at both the inflow, midportion and outflow. The THV was deemed noncircular if eccentricity was >10% at both the inflow, midportion and outflow.
Transcatheter heart valve thrombosis diagnosis, treatment and follow-up
Follow-up MDCT and echocardiography were performed by separate operators, but all imaging and clinical information were available to the threating physician. As per institutional policy, initiation of warfarin alone or in combination with antiplatelet therapy was recommended in patients with MDCT evidence of THV thrombosis, but the final decision was at the discretion of the treating physician taking into account the patient´s bleeding risk and preferences.
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Statistical analysis
The risk ratio (RR) with 95% confidence intervals and the chi-square are calculated to compare THV thrombosis risks ( Tables 1-3) . Left ventricular ejection fraction [LVEF] ≤35% at hospital discharge, use of a 29 mm THV and no post-TAVR warfarin treatment were entered into a log-linear model for binary data to estimate adjusted RRs for THV thrombosis (3) (4) (5) . Clinical implications of THV thrombosis were studied by comparing the distribution of various factors between THV thrombosis and non-THV thrombosis patients ( risk of mortality (STS PROM) was 5.3 (3.6-7.1). THV thrombosis risk was higher in patients with atrial fibrillation and eGFR ≤30 ml/min, and tended to be higher in males.
Results
Predictors of transcatheter heart valve thrombosis
Baseline characteristics
Procedural data, THV and pre-discharge echocardiographic characteristics
Information on THV thrombosis risk related to procedural data and pre-discharge echocardiographic characteristics are provided in Table 2 . A larger THV were associated with THV thrombosis (p=0.03). Otherwise, there were no differences in THV thrombosis risk in relation to procedural characteristics or THV function between groups. THV oversizing ≤17% vs >17% did not affect THV thrombosis risk significantly. Of note, the risk of THV thrombosis did not differ between the Edwards Sapien XT and the Sapien 3 valve.
Post-procedural antithrombotic regimen
Antithrombotic regimens from the TAVR procedure until routine follow-up visit 1 are outlined in Table 3 . The risk of THV thrombosis in patients not receiving warfarin was higher compared to patients receiving warfarin, 10.7% vs. 1.8%; RR, 95%CI: 6.09, 1.86-19.84. In patients receiving mono antiplatelet therapy, the risk of THV thrombosis was 18.8% (6/32).
Multivariable analysis of predictors of transcatheter heart valve thrombosis
In multivariable analysis, a 29 mm THV (RR, 95%CI: 2.89, 1.44-5.80) and no post-TAVR warfarin treatment (RR, 95%CI: 5.46, 1.68-17.7), but not LVEF ≤35% at discharge (RR, 95%CI: 2.21, 0.93-5.26), independently predicted THV thrombosis. There was no difference between the mean trans-THV gradient at predischarge vs. at routine follow-up visit 1 in the THV thrombosis group, 10±5 vs. 10±4 mmHg (p=1.00). The trans-THV mean gradient was higher among THV thrombosis patients ( Table 4 ). Left ventricular ejection fraction ≤35% was two-fold more frequent among patients with THV thrombosis compared to those without, 5 (18%) vs. 30 (8%) patients (p=0.08). There was no difference in 30-day complication rates between the two groups. Warfarin alone or in addition to antiplatelet therapy was prescribed in 4 (14%) and 17 (61%) patients, respectively. In the 3 (11%) patients already receiving warfarin, the target INR level was raised to 2.5-3. In 4 (14%) patients, routine antithrombotic therapy without warfarin was maintained, and additional downstream TEE and MDCT imaging were planned. Of these four patients, two experienced spontaneous THV thrombus regression, whereas two had THV thrombosis progression and warfarin was initiated. TEE and MDCT follow-up after 3 months of treatment showed complete thrombus resolution in 85% of cases (Figures 2 and 3) .
Incidence and clinical implications of transcatheter heart valve thrombosis
Follow-up and treatment of transcatheter heart valve thrombosis
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Obstructive transcatheter heart valve thrombosis
Five (18%) patients developed obstructive THV thrombosis with heart failure symptoms during the 12-month follow-up period. Details regarding these cases are presented in Online Table 2 . In 1 patient, obstructive THV thrombosis was diagnosed at routine follow-up visit 1, whereas 1 presented with symptoms of heart failure before and 3 patients 3-8 months after the routine follow-up visit 1. Four (80%) of these patients received mono antiplatelet therapy. No cases of THV obstruction were observed among patients without THV thrombosis.
Selected clinical characteristics, THV thrombus characteristics and outcomes in patients
with non-obstructive versus obstructive THV thrombosis are presented in the supplementary Table S3 . No patients with obstructive THV thrombosis received warfarin as part of post-TAVR antithrombotic therapy. Patients with obstructive THV thrombosis had involvement of more THV leaflets than patients with non-obstructive thrombus (1.3±0.5 vs. 2.4±0.5; p=0.0001), and the mean maximal leaflet thickness was significantly higher (4.2±1.8 mm vs. 7.5±1.3 mm; p=0.0007).
Routine follow-up visit 2
The median time from the TAVR procedure to routine follow-up visit 2 in the non-THV thrombosis group vs. the THV thrombus group was 360 (341-383) vs. 363 (348-375) days (p=0.45). Figure 1 , routine follow-up visit 2 data including clinical and echocardiographic assessment as well as mortality status were available in 335 (83%) patients.
As shown in
Twelve-month all-cause mortality was 17% (54/316) in the non-THV thrombosis group vs. 11% (Table 5 ). In patients with THV thrombosis, mean trans-THV gradient was lower at routine follow-up visit 2 vs. routine follow-up visit 1, 9±4 mmHg vs.
11±4 mmHg (p=0.03). Antithrombotic regimens at follow-up visit 2 are outlined in Online Table   4 .
Discussion
In this study comprising the largest to date and the first consecutive cohort having MDCT performed following TAVR with the Edwards XT or Edwards S3 THVs, the incidence of THV There is limited evidence on the optimal antithrombotic therapy following TAVR, and current recommendations regarding post-TAVR antithrombotic therapy have been empirically determined (12) (13) (14) . In a recent metaanalysis comparing aspirin vs. aspirin+clopidogrel following TAVR, there was no difference in the 30-day clinical and cerebrovascular adverse event rate, however a trend towards more bleeding in the aspirin+clopidogrel group was demonstrated (15) .
In this context, it should be acknowledged that in this study, mono therapy with aspirin was associated with a THV thrombosis risk of 25% and, importantly, all patients experiencing obstructive THV thrombosis, received mono antiplatelet therapy. Moreover, the present study indicates that a post-TAVR antithrombotic regimen without warfarin seems to predispose to THV thrombosis (5) . In line with these findings are recent data from a multicenter registry demonstrating that lack of anticoagulant therapy following TAVR seems associated with THV dysfunction (16) . The protective effect of anticoagulant therapy may explain the lower incidence of THV thrombosis among patients with atrial fibrillation in this study. Several ongoing randomized trials, such as the GALILEO trial (NCT02556203) and the POPular-TAVI trial (NCT02247128), will provide data on the use of non-vitamin K antagonist oral anticoagulants (NOAC) and antiplatelets after TAVR.
Currently, there is no consensus on how to treat THV thrombosis. As in previous studies, anticoagulation with warfarin was effective in the vast majority of patients in the present study (4, 5, 11, 17) . We and others have observed recurrence of THV thrombosis after discontinuation of warfarin, thus indicating that short-term warfarin treatment of THV thrombosis may not suffice in patients prone to developing THV thrombosis (5) . Furthermore, there is still uncertainty
regarding the natural history of THV thrombosis. Hypothetically, spontaneous THV thrombosis resolution may explain the discrepancy observed between the incidence of incidental THV thrombosis and clinically overt obstructive THV thrombosis. The data provided in this and previous studies suggest that follow-up MDCT in patients with THV thrombus will show either no regression or even progression in most patients who continue antiplatelet therapy only (4, 5) .
Moreover, we observed cases of incidental THV thrombosis progressing to clinically overt THV thrombosis with accompanying THV obstruction and symptoms of heart failure. These findings suggest that early detection and anticoagulation may be crucial in order to prevent deterioration of THV function. An alternative strategy to the one used in this study is "watchful waiting"
including serial clinical and imaging follow-up with anticoagulation being initiated only in the event of clinical THV thrombosis. However, 1 of 5 patients with obstructive THV thrombosis in this study did deteriorate despite initiation of anticoagulation. Furthermore, the clinical consequences of non-obstructive THV thrombosis may also include decreased long-term THV durability and increased risk of stroke, although assessment of the latter association is challenging due to the potential multiple mechanisms underlying TAVR-related stroke (5, 18) .
The safety of a "watchful waiting" strategy needs delineation in future studies.
We demonstrated for the first time an association between larger THV size and THV thrombosis. Ex vivo data have shown that local flow dynamics in the sinuses of Valsalva are modified upon THV implantation (19) . Whether these local flow dynamics are further modified by THV size/type, and thus play a causative role in development of THV thrombosis may be speculated. Additional procedural manipulation of the THV (e.g. post-dilatation), postdeployment THV geometry and degree of THV oversizing did not affect the incidence of THV thrombosis in this or in other studies (4, 5, 11) . Whether the rate of THV thrombosis varies with intraannuluar) leading to differences in local flow dynamics and variations in leaflet material (ie. porcine vs. bovine) may potentially account for differences in thrombogenicity. Recently, it was shown that platelet activation appears to be less enhanced in the Sapien 3 compared with Sapien XT, possibly due to the lower rate of post-TAVR aortic regurgitation. However, in the present study the incidence of THV thrombosis did not differ between these two THVs (20) . Studies including a larger number of THV thrombosis cases are needed in order to further elucidate specific risk factors for THV thrombosis.
Limitations
This study has the inherent limitations of an observational single-center design. The diagnosis of THV thrombosis was not confirmed by histology or autopsy, however THV leaflet thickening and restricted mobility was rapidly reversible by anticoagulation as documented by follow-up TEE and MDCT strongly underlining the thrombotic nature of these findings. The selection of variables included in the multivariable model for prediction of THV thrombosis, although based on knowledge from previous studies, was posthoc in nature. The present study design does not allow for conclusions on the natural history and management of THV thrombosis. Data in this real-world observational study were collected in a nonselected cohort of patients and involved multiple MDCT, echocardiography, and TAVR operators unblinded to the test results. There is no established consensus on the interpretation and management of imaging findings indicative of THV thrombus. In our center, the diagnostic strategy has previously been described (3) . It should be acknowledged that treatment decisions may have varied among observers taking into account also clinical observations, e.g. symptoms, bleeding risk and patient preferences. However, this study included all patients in a defined time period and represents M A N U S C R I P T
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consecutive data from a contemporary and relevant study cohort in a real-world setting. As well, impact of untreated THV thrombosis on clinical outcomes and structural valve degeneration is not answered by our data. This study is confined to the first 12 months after THV and therefore does not provide data on long-term impact or the occurrence of late THV thrombosis.
Concerning warfarin-treated patients, the International Normalized Ratio (INR) levels from discharge to routine follow-up visit 1 were not available. Finally, our findings may not be generalizable to other types of THVs.
Conclusion
The incidence of THV thrombosis in this large study was 7%. Larger THV size may predispose to THV thrombosis, whereas treatment with warfarin appears to have a protective 
